Gufic Biosciences Limited has informed the Exchange about Acquisition
GUFICBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.7 pts less than Nifty Microcap 250 and 6.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Gufic Biosciences' Board, meeting on February 13, 2026, approved the unaudited standalone and consolidated financial results for Q3 and nine months ended December 31, 2025, alongside a further investment in Selvax Pty Ltd, an Australian biotech firm. Standalone revenue from operations rose about 11% year-on-year to Rs. 23,109 lakhs in Q3, and about 12% to Rs. 68,842 lakhs for nine months. However, standalone net profit fell roughly 19% YoY to Rs. 1,556 lakhs in Q3 and about 31% to Rs. 4,257 lakhs for nine months, weighed by higher costs. Consolidated net profit for Q3 stood at Rs. 1,242 lakhs. Separately, the company will subscribe to 3,78,350 ordinary shares of Selvax at AUD 20 cents per share for up to USD 50,000, taking its post-investment holding to 16,85,350 shares. Selvax is developing an immunology-based treatment for solid tumours in humans and animals, and the deal is expected to close within four months.
Mixed quarter for shareholders — topline growth is healthy but margins and profits are under pressure, which the market may react to negatively. The Selvax investment is small in monetary terms (USD 50,000) but signals a strategic diversification into biotech and oncology, with no immediate earnings impact.